239 related articles for article (PubMed ID: 26398694)
1. AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS.
He L; Silva RA; Moshfeghi DM; Blumenkranz MS; Leng T
Retina; 2016 Mar; 36(3):492-8. PubMed ID: 26398694
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
[TBL] [Abstract][Full Text] [Related]
3. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
4. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
5. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
7. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
[TBL] [Abstract][Full Text] [Related]
8. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
[TBL] [Abstract][Full Text] [Related]
9. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
10. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
12. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
[TBL] [Abstract][Full Text] [Related]
13. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
14. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
15. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
[TBL] [Abstract][Full Text] [Related]
16. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
[TBL] [Abstract][Full Text] [Related]
17. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
[TBL] [Abstract][Full Text] [Related]
18. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
[TBL] [Abstract][Full Text] [Related]
19. Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.
He L; Silva RA; Ayoub N; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):542-9. PubMed ID: 26057757
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]